Free Trial Information
BioCentury | Apr 6, 2019
Finance

Everybody up

...approves HLX01 as a biosimilar to MabThera rituximab Shionogi & Co. Ltd. EC approves Rizmoic naldemedine...
Read More
BioCentury | Jan 8, 2019
Politics & Policy

CHMP recommendations of new active substances up in 2018

...unit of Johnson & Johnson (NYSE:JNJ) to treat non-metastatic castration-resistant prostate cancer (CRPC) and Rizmoic naldemedine...
Read More
BioCentury | Jan 5, 2019
Finance

Ready to launch

...RA EU, Japan, U.S. $61.4 Shionogi & Co. Ltd. (Tokyo:4507) / Purdue Pharma L.P. Symproic naldemedine...
Read More
BioCentury | Dec 21, 2018
Clinical News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

...agonist in July (see "FDA Approves Shionogi's Thrombocytopenia Drug "). CHMP also recommended Shionogi's Rizmoic naldemedine...
...Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Besremi ropeginterferon alfa-2b (AOP2014, P1101); Mulpleta lusutrombopag; Symproic naldemedine (S-297995...
...Former compound #), AG-014699 (Former compound #), rucaparib (Generic) Symproic (Brand), S-297995 (Compound #), naldemedine (Generic), Symproic...
Read More
BioCentury | Dec 14, 2018
Company News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

...agonist in July (see "FDA Approves Shionogi's Thrombocytopenia Drug" ). CHMP also recommended Shionogi's Rizmoic naldemedine...
...Pharma L.P. (Stamford, Conn.) market the oral peripheral μ opioid receptor (MOR; OPRM1) antagonist as Symproic...
...Former compound #), AG-014699 (Former compound #), rucaparib (Generic) Symproic (Brand), S-297995 (Compound #), naldemedine (Generic), Symproic...
Read More
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
Read More
BioCentury | Dec 1, 2017
Company News

Shionogi, Purdue launch OIC drug Symproic in the U.S.

...October, Shionogi & Co. Ltd. (Tokyo:4507) and Purdue Pharma L.P. (Stamford, Conn.) launched Symproic naldemedine (S-297995...
...supply of 90 tablets. Shionogi and Purdue said the U.S. Drug Enforcement Administration (DEA) descheduled Symproic...
...Ltd. (Tokyo:4507), Osaka, Japan Purdue Pharma L.P., Stamford, Conn. Product: Symproic naldemedine (S-297995) Business: Gastrointestinal Chris Lieu naldemedine S-297995 Symproic Purdue...
Read More
BioCentury | Apr 7, 2017
Finance

Fade to black

...RA Shionogi & Co. Ltd. (Tokyo:4507) / Purdue Pharma L.P. FDA and Japan approve Symproic naldemedine...
Read More
BioCentury | Mar 31, 2017
Clinical News

Symproic regulatory update

...FDA and Japan approved Symproic naldemedine from Shionogi to treat opioid-induced constipation (OIC). It is indicated...
...expect to launch the product in the U.S. in mid-summer. Purdue has rights to co-commercialize Symproic...
...& Co. Ltd. (Tokyo:4507), Osaka, Japan Product: Symproic (Rizmoic - EU) naldemedine (S-297995) Business: Gastrointestinal Alex Himes naldemedine Symproic Purdue...
Read More
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...atopic dermatitis PDUFA date 3/29/17 Shionogi & Co. Ltd. (Tokyo:4507) / Purdue Pharma L.P. Symproic naldemedine...
Read More
Items per page:
1 - 10 of 20